Bluebird Bio Inc logo

BLUE - Bluebird Bio Inc Share Price

$98.04 0.6  0.6%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £4.17bn
Enterprise Value £3.26bn
Revenue £41.5m
Position in Universe 1139th / 6415
Bullish
Bearish
Unlock BLUE Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BLUE Revenue Unlock BLUE Revenue

Net Income

BLUE Net Income Unlock BLUE Revenue

Normalised EPS

BLUE Normalised EPS Unlock BLUE Revenue

PE Ratio Range

BLUE PE Ratio Range Unlock BLUE Revenue

Dividend Yield Range

BLUE Dividend Yield Range Unlock BLUE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BLUE EPS Forecasts Unlock BLUE Revenue
Profile Summary

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 16, 1992
Public Since June 19, 2013
No. of Shareholders: 8
No. of Employees: 1,012
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 55,320,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BLUE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BLUE
Upcoming Events for BLUE
Similar to BLUE
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.